Evercore ISI Reaffirms Their Buy Rating on Ibotta, Inc. Class A (IBTA)
In a report released today, Mark Mahaney from Evercore ISI maintained a Buy rating on Ibotta, Inc. Class A (IBTA – Research Report), with ...
Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $5.00.
Elon Musk's $2 trillion spending cut goal is very ambitious, says Evercore ISI's Sarah Bianchi
Sarah Bianchi, Evercore ISI chief strategist of public policy, joins CNBC's 'The Exchange' to discuss the so-called DOGE ...
What’s next for Capri Holdings after ending Tapestry merger deal?
Capri and Tapestry have mutually agreed to terminate their planned merger. Capri CEO continues to see long-term potential in ...
Trump's economic policy to be net reflationary, fewer rate cuts expected, says Evercore ISI's Guha
Krishna Guha, Evercore ISI vice chairman, joins CNBC's 'Squawk Box' to discuss expectations for PPI, how a new Trump ...
"Strong case" for re-valuation higher of life insurance sector: Evercore ISI
Investing.com - A "strong case" can be made for a re-valuation higher of the life insurance sector, according to analysts at ...
Target is on watch after Evercore ISI warns of a negative earnings reaction
Evercore ISI initiates negative call on Target Corporation (TGT) ahead of earnings report, forecasting Q3 sales deceleration ...